Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QRX-3 in Hospitalized Patients with Acute Tubular Necrosis
NCT07161843Phase 3Not yet recruiting
- Sponsor
- Ebima Clifford Okundaye
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 3 trial of Eseronate in acute tubular necrosis (ATN), sponsored by Ebima Clifford Okundaye. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
Eseronate
03
Conditions
acute tubular necrosis (ATN)
Beyond the preview
Go deeper on NCT07161843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07161843.